VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Equid herpesvirus TK mutant vaccine NYVAC-EHV-1- vP1014
Vaccine Information Vaccine Information
  • Product Name: PR1
  • Vaccine Ontology ID: VO_0002957
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse, horse
  • TK gene engineering:
    • Type: Gene mutation
    • Description: This TK mutant is from Equid herpesvirus 1 (Slater et al., 1993).
    • Detailed Gene Information: Click Here.
  • Immunization Route: intranasal immunization
  • Vaccine Ontology ID: VO_0004771
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: vP1014, a vaccinia-based construct (NYVAC) coding for the immediate early gene (gene 64) of EHV-1 (Paillot et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response

Mouse Response

Horse Response

Horse Response

  • Vaccination Protocol: EHV-primed yearling ponies expressing this haplotype were vaccinated once (n = 1), three (n = 1), or four times (n = 2), and one pony was kept as an unvaccinated control (Paillot et al., 2006).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The ponies were challenged with EHV-1 (Paillot et al., 2006).
  • Efficacy: The results demonstrated that vaccination with a NYVAC-based construct coding for gene 64 stimulated CMI. This immune response alone did not protect against challenge infection. However, the study does illustrate that vaccinia-based vaccines can stimulate CMI in the horse and may therefore contribute to protection against disease caused by EHV-1 (Paillot et al., 2006).
References References
Slater et al., 1993: Slater JD, Gibson JS, Field HJ. Pathogenicity of a thymidine kinase-deficient mutant of equine herpesvirus 1 in mice and specific pathogen-free foals. The Journal of general virology. 1993; 74 ( Pt 5); 819-828. [PubMed: 8388018].